Description
NICOPATCHLIB, transdermal device, is a medication indicated for the treatment of tobacco dependence to relieve the symptoms of nicotine withdrawal in subjects wishing to stop smoking. For use in mild to moderately dependent smokers.
Nicotine replacement products reduce withdrawal symptoms. They work by releasing nicotine in relatively small doses, which gradually enter the bloodstream. The nicotine "hit" obtained by the smoker is replaced by a gradual release which makes withdrawal less painful, and also explains why these products are less addictive than cigarettes. Nicotine, when inhaled with tobacco smoke, creates a physical dependence because it passes very quickly into the bloodstream and the brain. When you stop smoking, the lack of nicotine can lead to unpleasant withdrawal symptoms: the urge to smoke, irritability, depression, difficulty concentrating, anxiety, sleep disorders, weight gain and increased appetite. Nicotine replacement products compensate for some of this nicotine withdrawal. They provide the nicotine that your body received when you smoked. Because they release nicotine slowly, they are not addictive. They ease withdrawal symptoms and allow you to focus on the other important aspects of quitting, the social, behavioural and psychological aspects of smoking. By using nicotine replacement products, you avoid inhaling the tar, toxic substances, carbon monoxide and irritating gases contained in smoke. NICOPATCHLIB 7 TRANSDERMAL PATCHES 7MG/24H :
Directions for use
For adults and children over 15 years of age only. Your degree of nicotine dependence will be assessed by the Fagerström test or by the number of cigarettes consumed per day. It will allow you to choose the dosage that corresponds to your needs. The dose should be increased if you experience symptoms of "withdrawal". It should be decreased if you feel signs of overdose: read the chapter on precautions for use and do not hesitate to ask your pharmacist for advice. The treatment is divided into 3 periods: Initial period: this lasts 3 to 4 weeks and will enable you to stop smoking. Follow-up treatment: this period consolidates the cessation of smoking and begins nicotine withdrawal. Therapeutic withdrawal: this period should enable you to stop the treatment. The whole treatment lasts on average 3 months. However, the duration of treatment may vary depending on individual response. The total duration of treatment should not exceed 6 months.
Complete cessation of smoking
3 to 4 weeks Treatment withdrawal 3 to 4 weeks Fargerström test score of 5 or more or Smokers of 20 or more cigarettes per day NICOPATCHLIB 21 mg/24h NICOPATCHLIB 14 mg/24h or NICOPATCHLIB 21 mg/24h* NICOPATCHLIB 7 mg/24h or NICOPATCHLIB 14mg/24h* then NICOPATCHLIB 7 mg/24h then NICOPATCHLIB 7 mg/24h** Fagerström test score less than 5 or Smokers of less than 20 cigarettes per day NICOPATCHLIB 14 mg/24h or increase to NICOPATCHLIB 21mg/24h* NICOPATCHLIB 14 mg/24h or NICOPATCHLIB 7 mg/24h** NICOPATCHLIB 7mg/24** or discontinuation of treatment. * Depending on the results of the withdrawal symptoms. ** In case of satisfactory results.
Stopping gradually
If you have difficulty quitting smoking completely, consult your doctor. He or she may consider letting you smoke for the first 2 weeks of starting NICOPATCHLIB Transdermal Devices. You can then start using NICOPATCHLIB 21 mg/24h transdermal device or NICOPATCHLIB 14 mg/24h transdermal device while you are still smoking. After 2 weeks, you stop smoking and continue treatment as described below. NICOPATCHLIB 7 mg/24h, transdermal device may be used in the follow-up and withdrawal phase.
Preparation to stop
2 weeks Initial phase 6 weeks Follow-up treatment 2 weeks Therapeutic withdrawal 2 weeks Fargerström test score of 5 or more or Smokers of 20 or more cigarettes per day NICOPATCHLIB 21 mg/24h NICOPATCHLIB 14 mg/24h NICOPATCHLIB 7 mg/24h Fargerström test score less than 5 or Smokers of less than 20 cigarettes per day NICOPATCHLIB 14 mg/24h or increase to NICOPATCHLIB 21mg/24h* NICOPATCHLIB 14 mg/24h or increase to NICOPATCHLIB 21mg/24h* NICOPATCHLIB 7 mg/24h or increase to NICOPATCHLIB 21 mg/24h* NICOPATCHLIB 7 mg/24h or discontinuation of treatment * Depending on the results of the withdrawal symptoms
Duration of treatment
The reduction in tobacco consumption should lead you gradually to complete cessation of smoking. This should be attempted as soon as possible within 6 months of treatment. If after 9 months of treatment, the attempt to stop smoking completely has failed, it is recommended that you seek advice from a health professional to consider an alternative strategy.
Mode of administration
Transdermal route. - Open the pouch with a pair of scissors and take out the transdermal device. - Remove the pre-cut protective sheet. - Apply NICOPATCHLIB immediately after opening to a dry skin surface with no skin lesions and little hair growth (trunk, upper arm or chest). - Do not apply to red, irritated or damaged skin. - To ensure perfect adhesion, press firmly on the entire surface for about 10 seconds with the palm of the hand. - Rub the edges firmly with your fingers to ensure that the device sticks properly. - The device should remain in place for 24 hours. - The application site should be changed every day, if possible avoiding replacing the device in the same place for a few days. - The device should be kept in its protective pouch until it is used. - It is essential to fold the device on itself after use before disposing of it in a safe place. - Any used or unused device should be kept out of the reach of children. - During handling, avoid contact with the eyes, nose and wash hands after application. - Do not cut the transdermal device. - In case of prolonged swimming in the sea or pool, you have 2 possibilities: * Before bathing, remove the transdermal device and immediately replace it on its holder. It can be stuck on a well-dried skin. * Cover the transdermal device with a waterproof adhesive bandage for the duration of the bath.
Contraindications
Never use this medicine in the following cases: If you do not smoke or if you are an occasional smoker, In case of allergy to one of the constituents, In case of a skin condition that may hinder the use of a transdermal system. In case of doubt, it is essential to ask your doctor or pharmacist for advice.
Warnings
Certain diseases require medical examination and monitoring before using this medicine. For example, in case of : - severe or moderate hepatic and/or renal insufficiency, - evolving gastric or duodenal ulcer, it is essential to consult your doctor before using this medicine. It is essential to keep the transdermal device out of the reach of children before and after use. After use, it is recommended that the transdermal device be folded onto itself before disposal. The therapeutic dose for adults could cause serious or even fatal poisoning in children. Precautions for use: Some signs indicate underdosing. If you feel, despite the treatment, a sensation of "withdrawal" such as - irritability, sleep disorders, - restlessness or impatience, - difficulty in concentrating, consult your doctor or pharmacist. It may be necessary to change the dosage of the medicine. Certain signs may indicate an overdose: if signs of overdose appear, i.e.: - nausea, abdominal pain, diarrhoea, - hypersalivation, - sweating, headache, dizziness, hearing loss, - general weakness, it is essential to adapt the treatment in progress with the help of your doctor or pharmacist. Taking or using other medicines: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Pregnancy
Stopping smoking during pregnancy is very important for you and your baby. Treatment with nicotine replacement products during pregnancy requires medical advice and monitoring. You should therefore consult the health professional who is following your pregnancy or your usual doctor or a doctor in a centre specialising in smoking cessation.
Breastfeeding
If you are a heavy smoker and do not plan to stop smoking, you should not breastfeed your child, but use artificial milk. The use of this medicine should be avoided while breastfeeding. However, if you wish to stop smoking and breastfeed your child, seek advice from your doctor or a doctor at a smoking cessation centre. For further information on contraindications, warnings, precautions for use, drug interactions, adverse reactions, you should consult the enclosed package insert for this product.
Composition
*Active substance: Nicotine 15mg for a 10 cm² transdermal device. One transdermal device delivers 7mg of nicotine per 24 hours. The other components are: acrylate vinyl acetate copolymer, methyl methacrylate and ethylene glycol dimethacrylate copolymer, polyester/polyethylene film, siliconised polyester film. Packaging: box of 7 transdermal patches. If your symptoms persist and/or if you experience any adverse effects you should consult your doctor.
100% secure payment, Customer Satisfaction
Order shipped within 24 hours from Monday to Friday*
